A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

NCT06626919

Status	RECRUITING
Phase	Phase 1
Sponsor	Arcellx, Inc.
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Subject must be 18 years of age or older
- Must have MGFA clinical classification Grades 2-4A at time of screening
- Subject must have clinically active disease and requiring ongoing therapy for GMG
- MG-ADL score 6 and QMG score \>10 at screening
- GMG specific autoantibodies must be above the reference laboratory ULN

Exclusion (5)

- Subject is pregnant or breastfeeding
- Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion
- Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager
- Previous thymectomy within 6 months of screening
- Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator

Locations (13 total)

UCLA Medical Center, Los Angeles, California, United States
University of California, Irvine, Orange, California, United States
Stanford Hospital, Palo Alto, California, United States
... and 10 more locations